CATX HealthcareBeta data

Perspective Therapeutics, Inc.

$0.88-15.38%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Medical Devices
Country: United States
Market cap: 100.5M USD
Enterprise value: -49.1M USD
Full-time employees: 163

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 1.80 vs a peer median of 0.63)bigger price swings (beta 1.80 vs peers 0.63)
About average: risk (debt, liquidity and share-price swings)risk
Not enough data: growth

Would rank #874 of 1,157 fully scored healthcare companies (bottom 25%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 423% from December 2022 to December 2025.
Perspective Therapeutics had 423% more shares at December 2025 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Perspective Therapeutics had 423% more shares at December 2025 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Cash exceeds market value plus debt. Its cash is worth more than its market value plus debt.
Perspective Therapeutics's cash is larger than its market value and debt combined (enterprise value at or below zero). The market is valuing the operating business at nothing or less, which is rare.Perspective Therapeutics's cash is larger than its market value and debt combined. The market is valuing the operating business at nothing or less, which is rare.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Perspective Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss over the last 12 months.
Perspective Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

37/ 100

Oct 5 28 → Nov 4 37 (+9)

Fundamentals: Yahoo Finance, not primary filings

Valuation

Is the price right?

33/100

Weak

2/3 inputs reported · Partial data

Since last year: ▲ Stronger

Share count down 59.3%

Valuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-151.1%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yieldUnavailable

Cash exceeds market value plus debt, so EBITDA yield is not meaningful and is left out · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0401 · MAD: 0.0401

Free cash flow yield-120.6%

Yahoo Finance · trailing 12 months · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield322.6%

Yahoo FinanceOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 0 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

19/100

Weak

2/3 inputs reported · Partial data

Since last year: No major change

Why

Weaker than most peers on:

▼ ROA
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating marginUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0706 · MAD: 0.1217

Return on assets-29.7%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -5.84Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-35.7%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -4.03Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-39.6%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Since last year: No major change

Why

Mixed versus peers:

▲ Debt / equity
▲ Current ratio
▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.80

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -3.49Sector median: 0.6250 · MAD: 0.3380

Current ratio6.61×

Yahoo FinanceReported value33% base weight · Z-score 2.90Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.01×

Yahoo FinanceReported value33% base weight · Z-score 1.03Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Perspective Therapeutics

Is Perspective Therapeutics getting weaker?: Its latest SEC filing (Aug 10, 2026) was mixed: some things better, some worse: 12-month revenue fell 84.0%; share count down 59.3%. Its overall score is unchanged at 37/100 since Oct 28, 2026.
How is Perspective Therapeutics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 33/100 against 1,393 healthcare peers. Earnings yield -151.1% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -151.1% vs peers 1.5% (weaker than 100% of peers).
Is Perspective Therapeutics growing?: Insufficient data: 0 of 3 inputs reported (at least 2 needed).
How profitable is Perspective Therapeutics?: Less profitable than most of its peers. Profitability scores 19/100 against 1,393 healthcare peers. Return on assets -29.7% vs a peer median of 1.7% (weaker than 86% of peers).Return on assets -29.7% vs peers 1.7% (weaker than 86% of peers).
How risky is Perspective Therapeutics?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.01× vs a peer median of 0.22× (stronger than 88% of peers).Debt / equity 0.01× vs peers 0.22× (stronger than 88% of peers). Beta 1.80 vs a peer median of 0.63 (weaker than 92% of peers).Beta 1.80 vs peers 0.63 (weaker than 92% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Year ended Dec 31, 2023 · filed Aug 10, 2026 · compared with the year ended Dec 31, 2022

Mixed: some things better, some worse

12-month revenue fell 84.0%
Share count down 59.3%

Worth watching: Perspective Therapeutics is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous year	Latest year	Change
Revenue (12 months)	9.0M USD	1.4M USD	−84.0%
Net income (12 months)	−10.8M USD	−116.4M USD	+982.1%
Operating margin	-126.9%	-8733.1%	−8606.2 pts
Free cash flow (12 months)	−10.7M USD	−121.2M USD	+1034.4%
Debt	1.8M USD	1.7M USD	−10.3%
Cash	28.3M USD	48.5M USD	+71.2%
Shares outstanding	280.6M	114.2M	−59.3%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one year at a time.

Industry valuation context

Industry: Medical Devices · 33 companies

Valuations in Medical Devices are near the bottom of their range since 2016.

7% of months since 2016 were valued lower than now.
4% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values −8% and earnings +33% (medians): earnings grew faster than prices.
Median price-to-sales is +20% vs the whole market, against a usual +109%.

2016Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY Jun 2022	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	0.0%	—	100.0%	—	—	—
Operating margin	-59.5%	—	-2855.0%	—	—	—
Net margin	-67.4%	—	-3243.2%	—	—	—
Return on assets (ROA)	-11.3%	-18.5%	-47.5%	-23.2%	-38.6%	▼ 15 pts
Return on equity (ROE)	-11.9%	-19.7%	-61.9%	-27.3%	-49.8%	▼ 23 pts
Free cash flow margin	-73.9%	—	-2648.9%	—	—	—
Current ratio	26.18×	17.07×	1.07×	12.68×	5.17×	▼ 59%
Quick ratio	25.57×	16.62×	—	—	—	—
Debt to equity	—	0.00×	0.02×	0.01×	0.01×	▲ 37%
Interest coverage	—	—	-487.39×	—	—	—

CATX price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 1.80 vs a peer median of 0.63)bigger price swings (beta 1.80 vs peers 0.63)

About average: risk (debt, liquidity and share-price swings)risk

Not enough data: growth

Would rank #874 of 1,157 fully scored healthcare companies (bottom 25%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 423% from December 2022 to December 2025.

Perspective Therapeutics had 423% more shares at December 2025 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Perspective Therapeutics had 423% more shares at December 2025 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Cash exceeds market value plus debt. Its cash is worth more than its market value plus debt.

Perspective Therapeutics's cash is larger than its market value and debt combined (enterprise value at or below zero). The market is valuing the operating business at nothing or less, which is rare.Perspective Therapeutics's cash is larger than its market value and debt combined. The market is valuing the operating business at nothing or less, which is rare.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Perspective Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss over the last 12 months.

Perspective Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about Perspective Therapeutics

Is Perspective Therapeutics getting weaker?

Its latest SEC filing (Aug 10, 2026) was mixed: some things better, some worse: 12-month revenue fell 84.0%; share count down 59.3%. Its overall score is unchanged at 37/100 since Oct 28, 2026.

How is Perspective Therapeutics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 33/100 against 1,393 healthcare peers. Earnings yield -151.1% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -151.1% vs peers 1.5% (weaker than 100% of peers).

Is Perspective Therapeutics growing?

Insufficient data: 0 of 3 inputs reported (at least 2 needed).

How profitable is Perspective Therapeutics?

Less profitable than most of its peers. Profitability scores 19/100 against 1,393 healthcare peers. Return on assets -29.7% vs a peer median of 1.7% (weaker than 86% of peers).Return on assets -29.7% vs peers 1.7% (weaker than 86% of peers).

How risky is Perspective Therapeutics?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.01× vs a peer median of 0.22× (stronger than 88% of peers).Debt / equity 0.01× vs peers 0.22× (stronger than 88% of peers). Beta 1.80 vs a peer median of 0.63 (weaker than 92% of peers).Beta 1.80 vs peers 0.63 (weaker than 92% of peers). A relative measure, not a bankruptcy probability.

Previous year

Latest year

Change

Revenue (12 months)

9.0M USD

1.4M USD

−84.0%

Net income (12 months)

−10.8M USD

−116.4M USD

+982.1%

Operating margin

-126.9%

-8733.1%

−8606.2 pts

Free cash flow (12 months)

−10.7M USD

−121.2M USD

+1034.4%

Debt

1.8M USD

1.7M USD

−10.3%

Cash

28.3M USD

48.5M USD

+71.2%

Shares outstanding

280.6M

114.2M

−59.3%

Key ratios

FY Jun 2022

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

0.0%

—

100.0%

—

Operating margin

-59.5%

—

-2855.0%

—

Net margin

-67.4%

—

-3243.2%

—

Return on assets (ROA)

-11.3%

-18.5%

-47.5%

-23.2%

-38.6%

▼ 15 pts

Return on equity (ROE)

-11.9%

-19.7%

-61.9%

-27.3%

-49.8%

▼ 23 pts

Free cash flow margin

-73.9%

—

-2648.9%

—

Current ratio

26.18×

17.07×

1.07×

12.68×

5.17×

▼ 59%

Quick ratio

25.57×

16.62×

—

Debt to equity

—

0.00×

0.02×

0.01×

▲ 37%

Interest coverage

—

-487.39×

—